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Abstract
For an infecting bacterium the human body provides several potential ecological niches with both internally (e.g. host
immunity) and externally (e.g. antibiotic use) imposed growth restrictions that are expected to drive adaptive evolution in
the bacterium, including the development of antibiotic resistance. To determine the extent and pattern of heterogeneity
generated in a bacterial population during long-term antibiotic treatment, we examined in a monoclonal Mycobacterium
tuberculosis infection antibiotic resistant mutants isolated from one patient during a 9-years period. There was a progressive
accumulation of resistance mutations in the infecting clone. Furthermore, apparent clonal sweeps as well as co-existence of
different resistant mutants were observed during this time, demonstrating that during treatment there is a high degree of
dynamics in the bacterial population. These findings have important implications for diagnostics and treatment of drug
resistant tuberculosis infections.
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Introduction
In 2009, tuberculosis disease (TB) due to Mycobacterium tubercu-
losis infections caused an estimated 1.3 million deaths globally [1].
When active TB is manifested the infection is normally treated
with antibiotics, thereby providing an external pressure for the
selection of antibiotic resistant bacilli. The risk of resistance
development will be determined by a number of different factors,
including the antibiotic selective pressure (set by the number,
dosing and quality of the used drugs), any pre-existing resistances
in the infecting clone, the immune status of the treated individuals
and their compliance with the drug regime [2–4]. In addition,
since all resistance development in M. tuberculosis occurs via
mutational changes in the chromosome, the bacterial population
size and the bacterial mutation rate will also affect the probability
by which resistant clones appear de novo during treatment [5].
Furthermore, the ability of a resistant clone to grow and rise in
frequency in the treated individual is influenced by the effect of the
resistance on bacterial fitness [6,7].
The primary drugs used in treatment of M. tuberculosis infections
are isoniazid and rifampicin and resistance to these drugs may be
caused by mutations in a number of genes, including inhA, katG,
and ndh, (isoniazid) and rpoB (rifampicin) [8–11]. Other primary
drugs used include ethambutol, pyrazinamide and streptomycin
where mutations in the embB (ethambutol), pncA (pyrazinamide)
and rpsL/rrs (streptomycin) genes confer resistance [12–14]. In
addition, there are several second-line antibiotics available but
many of them are less efficacious, give more side-effects and are
more expensive than the first-line drugs. Examples of second-line
drugs include aminoglycosides, polypeptides, fluoroquinolones,
thioamides, cycloserine and p-aminosalicylic acid [15].
The effects of resistance to rifampicin, isoniazid and strepto-
mycin on fitness have been examined in M. tuberculosis and other
bacterial species, and depending on which gene is mutated and the
particular mutation the effect might range from no effect to a
severe reduction in fitness. For example, most mutations in rpoB
seem to reduce fitness [16–19]. In contrast, the fitness effects of
mutations in the rpsL and katG genes vary greatly depending on the
specific mutation. Thus, the katG mutation Ser315RThr and rpsL
mutation Lys42RArg have no or small effects on fitness, while
the Thr275RPro (katG) and Lys42RThr and Lys42RAsn (rpsL)
mutations significantly reduce fitness [20–26]. As expected, the
frequencies by which these different mutants are recovered
clinically from patients correlate with their fitness measured in
vitro [17,24–26]. These findings demonstrate that fitness is a major
determinant of the ability of these different resistant mutants to
spread and establish infections [7,25].
Even though several studies of the long-term dynamics of
drug resistance in rapidly mutating viruses with large populations
have been performed [27,28], less is known about resistance
dynamics in bacteria. Partly this is because the lower mutation
rates in bacteria, and the resulting lower rates by which drug
resistant variants appear, imply that there is less dynamics in the
population. However, some studies of bacterial diversity in, for
example, Pseudomonas aeruginosa [29,30] and Helicobacter pylori
[31,32] suggest that also in bacterial infections population
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21147heterogeneity might be considerable, especially during long-term
or chronic infections.
To address the extent of heterogeneity and dynamics in
antibiotic resistant variants during a monoclonal infection in a
host, we examined serial M. tuberculosis Beijing isolates obtained
from one patient during a 9-year period of infection and disease
where the successive accumulation of resistance mutations
ultimately made the infection untreatable and caused death of
the patient. Her isolates belonged to the W-Beijing family of M.
tuberculosis, which are especially prevalent in East Asia and Eastern
Europe [33–35], and are genetically identified by their character-
istic IS6110 and spoligotypes patterns and katG463and gyrA95
mutations [35]. Moreover, we examined the heterogeneity and
dynamics with respect to aminoglycoside resistance within 10
single colony isolates (sub-clones) derived from each of the original
serial patient isolates. Analysis of these sub-clones showed that
there is a high degree of dynamics in the infecting bacterial
population, including successive changes in antibiotic resistance
types and bacterial fitness. These findings have important
implications for treatment and diagnostics of antibiotic resistance
in infected individuals.
Materials and Methods
Isolates
The isolates that were characterized were clinical isolates
obtained from the same patient during a period of 9 years (1991–
1999). These isolates were kept frozen at 270uC in Middlebrook
7H9 broth containing 10% glycerol. A fresh aliquot was taken for
analysis and prior to all experiments, the isolates were cultured on
Lowenstein-Jensen slants for 3 to 4 weeks at 37uC. The isolates
and the time of isolation together with their drug resistance
patterns are listed in Table 1.
Drug Susceptibility Testing of Serial Isolates
Drug susceptibility testing of the isolates to the various drugs
(isoniazid, rifampicin, streptomycin, ethambutol, amikacin) were
performed using the BACTEC 460TB system according to the
instructions of the manufacturer.
DNA Extraction
For DNA extraction, the isolates were first grown on Low-
enstein-Jensen (LJ) medium. Bacterial cells were then transferred
into 1.5 ml micro-centrifuge tubes containing 250 mlo f1 6 TE
buffer using a sterile loop followed by killing by heating at 80uC for
1 hr. Cells were then centrifuged at 13,000 rpm for 2 min. The
supernatant was discarded and the pellet resuspended in 500 mlo f
150 mM NaCl, followed by centrifugation. This was repeated
once. Finally, the DNA pellet was resuspended in 25 mlo fT E
buffer.
Amplification of DNA by PCR and Sequencing
PCR reactions were carried out in a 50 ml volume containing
0.5 mM of each primer, 200 mM of each dNTP, 5 mlo f1 0 6PCR
buffer, 0.25 ml of AmpliTaq Gold DNA polymerase, 1 ml of DNA
and 2 mM MgCl2 except for the primer pair used to amplify the
1400 region of rrs, for which the MgCl2 concentration was 3 mM.
The primers, size of fragments targeted for amplification and
cycling conditions are listed in Table S1. The GeneAmpH PCR
System 9700 was used for running PCR and sequencing reactions.
PCR products were purified using GFX
TM PCR and Gel Band
Purification Kit (Amersham Pharmacia Biotech). The same
primers as used for PCR were used in cycle sequencing reactions.
The sequenced genes were katG, rpoB, rpsL, embB and rrs.
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21147Sequencing was performed using both forward and reverse
primers. Sequencing reactions were run with an initial denatur-
ation at 96uC for 1 min followed by 25 cycles each at 96uC for
10 sec, 50uC for 5 sec and 60uC for 4 min. Sequences were
obtained using ABI PRISM 3100 Genetic Analyzer. Mutations
were identified by importing sequencing products into the
BLAST2 nucleotide sequence alignment tool.
Analysis of aminoglycoside resistance mutation spectra
in cub-clones
zzzzBecause initial sequencing of the gene (rpsL and rrs) segments
in which mutations occur to cause streptomycin and amikacin
resistance in the successive serial isolates revealed changing patterns
(wild-type to mutant and back to wild-type again), each of the 8
isolates were first grown on duplicate plates on Middlebrook 7H10
medium containing 10% OADC enrichment (M7H10 medium) to
obtain single colonies. Then, 10 single colonies (sub-clones) were
randomly picked from two different plates on day 16 of culture and
grown in Middlebrook 7H9 medium containing 10% ADC
enrichment and 0.1% Tween 80 (M7H9 medium) for 3 weeks
followed by inoculation onto LJ medium. DNA extraction, PCR
amplification and sequencing were performed as described above
for the isolates to identify the spectrum of mutations.
Molecular Typing of Serial Isolates
The serial isolates were typed by both spoligotyping [36] and
restriction fragment length polymorphism (RFLP) [37]. The
similarities of the RFLP patterns were determined by using
BioNumerics version 3.0 software (Applied Maths, Sint Maarten
Latem, Belgium). Results are shown in Figure S1.
Determination of relative fitness by competition
experiments
To determine the relative fitness of the various isolates, head-to-
head competitions were performed in liquid cultures. Isolate 1.1
(isolated on 2/4/91 from the patient) was arbitrarily chosen as the
parent and all competitions were then performed between this
parental isolate and sub-clones from subsequent isolates. Since the
parent isolate was susceptible to rifampicin and all the subsequent
isolates were highly resistant, rifampicin was used to distinguish the
parent and competitors. The parental isolate and the competitors
were inoculated from Lowenstein-Jensen slants and grown
separately in 7H9 medium containing 0.1% Tween 80 for one
week prior to use. After homogenization of the cultures by
sonication for 5 min, optical densities of the parental and
competitors were adjusted to the same value (A600=0.1) and then
10 ml of the parental and 30 ml of the competitor bacterial
suspensions were mixed in 20 ml of 7H9 medium. Since we
expected that the mutants would be outcompeted, competition
experiments were started with mutants in slight excess (3:1) to
increase the range where the mutants could be followed.
Immediately after mixing, dilutions were prepared from each
mixed culture and plated in duplicate on both drug-free and
rifampicin-containing (2 ug/ml) M7H10 plates. Cultures were
incubated in M7H9 medium at 37uC with regular shaking and
the plating procedure was then repeated after 14 days of growth.
The number of colony forming units (CFUs) on the agar plates
was counted after 25 days of incubation at 37uC. The CFU counts
of the wild type were obtained by subtracting the CFU on
drug-containing plates from the total CFU on drug-free plates.
The competition index (CI) was calculated as the ratio of
CFU (mutant)14 days/CFU (parental)14 days divided by CFU
(mutant)0 days/CFU (parental)0 days. A CI value .1 indicates that
the competitor outcompeted the parent and ,1 the opposite.
Fourteen days of incubation correspond to approximately 15–20
generations of growth for the parental strain. The data presented
represent the averages of two independent experiments for each of
the mutant types. Control experiments showed that the plating
efficiency of the resistant mutants was unaffected by the presence
of rifampicin.
Ethics Statement
This in vitro study was carried out on a number of clinical isolates
of M. tuberculosis obtained from one patient with multi-drug-
resistant tuberculosis. The isolates were collected during the period
1991 to 1999 and kept at the strain collection of the Swedish
Institute for Infectious Disease Control. The patient died in 2000,
four years before the study was initiated, and the results obtained
did not in any way affect the clinical treatment or outcome, i.e. the
samples were taken as part of routine clinical care and specific
consent was therefore not needed and acquired. Exemption from
ethical approval was provided by the institutional review board at
the Karolinska Institute (Regional Ethical Review Board in
Stockholm, FE 289 171 77 Stockholm) who stated that this in
vitro study on clinical isolates and their drug resistance carried out
at our laboratory is excluded from the demand of a specific ethical
permission.
Results
Patient data, antibiotic prescription and antibiotic
resistance from 1991–1999
At the time of diagnosis of lung tuberculosis, March 1991, the
Swedish female patient was 19 years old and she was then
intermittently antibiotic treated until she died of tuberculosis in
July 2000. The treatment and resistance pattern is shown in
Table 2 and indicates the types of antibiotic used during the period
1991–2000 and the resistance pattern of the bacteria. Standard
drug susceptibility testing [using the BACTEC 460TB system of
the serially obtained bacterial samples showed that the isolates
exhibited resistance to an increasing number of drugs (Table 1).
The first isolate was resistant to isoniazid only. The second isolate
also acquired resistance to rifampicin. The third through seventh
isolates were resistant to isoniazid, rifampicin and streptomycin
and this triple resistance developed within about six months
(Table 1). The eighth isolate was resistant to all these drugs and to
the second-line drug amikacin.
IS6110 based RFLP and spoligotyping indicates the
presence of one clone during infection
The IS6110 RFLP patterns of the bacterial isolates isolated
from 1991 to 1999 were identical as shown in Fig. S1. In addition,
the spoligotyping pattern showed that they had the 9-band
hybridisation to spacers 35–43 characteristic of Beijing isolates
(Fig. S1). These data strongly suggest that the patient carried the
same single clonal type during 9 years of infection and that no re-
infection with other strains occurred during this period.
Heterogeneity of resistance mutations between different
time points
The respective gene fragments of these eight isolates were
subjected to PCR and DNA sequencing to detect the presence of
potential mutations in the katG, rpoB, rpsL, embB and rrs genes.
Initial sequencing revealed that all eight isolates carried the
AGC315RACC mutation responsible for isoniazid resistance
and an additional CGG463RCTG mutation in katG. The
Dynamics of Antibiotic Resistant Mycobacterium
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21147CGGRCTG mutation at codon 463 has been shown to be
prevalent in Beijing family isolates and is not associated with INH
resistance [34,38,39]. As shown in Table 1, all but the first isolate
harboured the GAC516RGTC mutation in the rpoB gene. None
of the isolates carried any mutations in the embB gene but
ethambutol resistance was observed (Table 1), implying that
ethambutol resistance occurred by an embB-independent mecha-
nism [40,41]. All isolates were susceptible to amikacin except for
the last isolate (isolate 8), which carried the A1400RG mutation in
rrs, which has been shown to be responsible for amikacin resistance
in both clinical and in vitro isolates of M. chelonae, M. abscessus and
M. tuberculosis [42,43].
Dynamics of streptomycin resistance mutations within
and between sub-clones
The initial sequencing of all isolates showed the presence of one
or the other of at least three different mutations in rpsL or rrs.
These were the AAG87RAGG and AAG42RAGG mutations in
rpsL, and A513RCi nrrs in isolates 3–8. These data thus suggested
that there might be heterogeneity with regard to the streptomycin
resistance mutations within the bacterial population isolated from
each time point (note that the initial testing of drug susceptibility
and sequencing of the rpsL and rrs genes were performed on
bacterial populations obtained from each time point and that had
not been single-cell colony purified). To assess the potential genetic
heterogeneity within each population, the rpsL and rrs gene
segments responsible for streptomycin resistance were sequenced
from 10 randomly selected sub-clones obtained from the eight
time points (Table 3).
From both the susceptibility data and sequencing of the rpsL
gene, sub-clones of isolates 1 and 2 were shown to be sensitive to
streptomycin and wild-type in rpsL (Tables 1 and 4). Most sub-
clones of subsequent isolates 3, 4 and 5 harbored the
AAG87RAGG streptomycin resistance mutation, with only two
sub-clones harboring the AAG42AGG mutation in rpsL (sub-
clones 3.8 and 4.3) or A513C mutation in rrs (sub-clone 3.2)
(Table 3). (The A513RC mutation alone in rrs is known to confer
streptomycin resistance in E. coli [44] and clinical isolates of M.
tuberculosis [14]). Thus, the heterogeneity was evident within and
between the sub-clones (e.g., 3.2 and 3.8, which are different from
each other and the other sub-clones of isolate 3 as well as from the
sub-clones of isolate 5, Table 3). A sub-clone of isolate 5 (5.5)
yielded ambiguous sequencing result in rpsL (AGG87RANG. One
sub-clone (5.10) was found to be wild-type for both rpsL and rrs.
With regard to the streptomycin resistance mutations, at least
four different types (rpsL87AGG, rrsA513C, rpsL42AGG and
rpsL42AGG +rrsA1400G) were identified during the sampling
period. This is likely to be an underestimate since we only
examined 10 independent sub-clones for each time point and
during the period 1993–1999 sampling was sparse. A shift in the
bacterial population from AAG87RAGG to the AAG42RAGG
variant is seen from isolate 6 onwards (except for isolate 7 most
sub-clones of which carried the A513RC mutation in rrs, with
only two of its sub-clones [7.1 and 7.7] carrying the AA-
G42RAGG mutation).
Fitness and frequencies of different streptomycin
resistant types
To determinethe competitivefitnessof the differentstreptomycin
resistant mutants isolated during the course of the infection, we
performed in vitro competition experiments where the different
streptomycin resistant sub-clones were competed against a sub-
clone obtained from the first isolate obtained in 1991 (resistant to
isoniazid and susceptible to rifampicin, ethambutol, streptomycin
and amikacin, see 1 [S91-222 (1, parent)] in Table 4. In vitro
competitions in rich culture medium have been shown in previous
Table 3. Heterogeneity in types of streptomycin resistance mutations isolated during treatment.
Parent isolate Sub-clones Gene
rpsL
(numbers indicate
amino acid position) rrs
Nucleotide A513 Nucleotide A1400
1 (S 91-222) 1.1–1.10 wt wt wt
2 (S 91-224) 2.1–2.10 wt wt wt
3 (S 91-263) 3.1,3.3–3.7,3.9–3.10 AAG87RAGG wt wt
3 (S 91-263) 3.2 wt A513RCw t
3 (S 91-263) 3.8 AAG42RAGG wt wt
4 (S 92-001) 4.1–4.2,4.4–4.10 AAG87RAGG wt wt
4 (S 92-001) 4.3 AAG42RAGG wt wt
5 (S 92-031) 5.1–5.4,5.6,5.8–5.9 AAG87RAGG wt wt
5 (S 92-031) 5.5 AAG87RANG wt wt
5 (S 92-031) 5.7 ND wt wt
5 (S 92-031) 5.10 wt wt wt
6 (S 93-007) 6.1–6.10 AAG42RAGG wt wt
7 (S 93-021) 7.1,7.7 AAG42RAGG wt wt
7 (S 93-021) 7.2–7.6, 7.8–7.10 wt A513RCw t
8 (S 99-293) 8.1–8.7,8.9–8.10 AAG42RAGG wt A1400RG
8 (S 99-293) 8.8 wt wt A1400RG
doi:10.1371/journal.pone.0021147.t003
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which the resistantmutants arerecoveredinclinical settings[17,24–
26]. The relative fitness of the first isolate was set to 1.0 and all
subsequent isolates were compared to this strain (Table 4). When
comparing isolates with same resistance mutation rpsL87AGG (i.e.
3.1 and 4.4 with 5) it can be seen that in some cases fitness appeared
to increase over time (competition index [CI] increased from 0.3 to
8). Similarly, when comparing the isolates with mutation rrsA513C
(i.e. 3.2 with 7.2) the competition index was increased from ,0.01
to 1, suggesting a substantial increase in fitness. However, there
were also exceptions to this trend such that less fit mutants appeared
over time (for example, replacement of the fit 1992, rpsL87AGG
mutant by the less fit 1993, rpsL87AGG). Thus, we could not
observe any general trend that fitness was increased over time.
Discussion
The presented resultsshow that there is extensivedynamics inthe
bacterial population during a long-term M. tuberculosis infection. As
expected, over time and with cumulative antibiotic exposure there
was a progressive accumulation of resistances in the infecting clone.
More unexpected was the dynamics observed for the streptomycin
resistant sub-clones, where successive clonal sweeps as well as
transient co-existence of different streptomycin-resistant variants
were observed during the 9-year period (Table 3). During growth in
the patient fitness of the antibiotic resistant sub-clones changed
(Table 4), suggesting that they adapted to the fitness costs associated
withtheresistancemutations.Thus,inseveralcasesfitnessappeared
to increase over time but in other cases fitness was reduced,
suggesting that the within host dynamics is complex and that the
growth rate measured in vitro is not necessarily a direct predictor of
bacterial growth and survival within a patient.
It is commonly assumed in bacterial infections that one resistance
type (primary or acquired) goes to fixation in the population in
response to an imposed antibiotic pressure. Instead of such fixation,
we observed successions as well as co-existence of resistant mutants
(Table 3). These results are of relevance both from an evolutionary
point of view as well as for diagnostics and treatment of TB. As seen
from previous in vitro fitness assays, severalof the common resistance
mutations (e.g. rpsL87AGG and rrsA513C) found in clinical isolates
of M. tuberculosis cause a reduction in fitness [24–26,45]. These
mutations were also found in isolates from this patient. In some
certain cases, these resistant mutants either disappeared or were
replaced by other more fit mutants (e.g. rpsL87AGG was replaced
byrpsL42AGGfrom1992 to1993)or theirfitnesswas increased due
to other unknown mutations (e.g. subclones 3.1 and 4.4 versus 5,
and subclones 3.2 versus 7.2) [19,45,50]. Thus, it is possible that
more fit multi-resistant mutants may be selected during treatment
and subsequently spread to other individuals [6,25]. Interestingly,
the succession of streptomycin resistant rpsL mutants (i.e.
rpsL87AGG was replaced by rpsL42AGG) observed in our isolates
is reminiscent of that seen in a previous study where serial isolates
from a single patient showed a similar succession of rpsL mutant
types [46]. Furthermore, heterogeneity in resistance types can
involveotherdrugsthanstreptomycin,asshownforethambutoland
fluoroquinolones where parallel evolution in distinct lung compart-
ments from a single founder strain was suggested to generate
heterogeneity in resistance-associated alleles for isolates with
identical IS6110 RFLP pattern [47].
It has been shown that heterogeneity exists in the resistant bacterial
populations within the host [46,47] and it is conceivably that the
frequencies with which different drug resistant mutants are isolated in
patients partly is determined by their differences in fitness. Support
for this notion comes from the observation that a positive correlation
between the frequency of isolation of resistant mutants and their
relative fitness (e.g., Ser531RLeu in rpoB (rifampicin resistance),
Lys42RArg in rpsL (streptomycin resistance), Ser315RThr in katG
(isoniazid resistance) has been reported for M. tuberculosis [5,17,19,23–
26]. There is ample support for compensatory evolution of fitness
costs associated with resistance mutations [16,20–21,45–52], and it is
conceivable that such evolution also influences the fitness of the
resistant mutants studied in this and other work. Thus, the differences
in fitness observed between sub-clones with the same resistance
mutations might indicate compensatory evolution. However, we
cannot exclude the possibility that the observed fitness differences are
caused by other fitness-altering genetic changes, unrelated to the
resistance mutations.
Finally, our findings are relevant from the point of view of
resistance diagnostics. Thus, most current clinical and research
procedures to determine resistance patterns are based on
examination of single isolates from a given disease episode with
the assumption that this isolate is representative of a homogenous
bacterial population. Recent studies have shown that this
assumption is invalid and demonstrated the occurrence of both
mixed clonal infections as well as exogenous re-infection where a
patient is re-infected by a second clone during a recurrent episode
[53,54]. This study demonstrates that within a specific clone there
is also extensive heterogeneity with respect to the resistant mutants
selected and maintained over time. Since fitness and resistance
levels might vary between resistant types it is important to know
the population composition at different time points to assure that
the proper drug combinations are used. To obtain a measure of
this heterogeneity several independent bacterial clones needs to be
examined from each patient sample. Furthermore, the heteroge-
neity in resistance mutations observed here is most likely an
underestimate since we only examined streptomycin resistance,
sampling was sparse during some time intervals (i.e. 1993–1999),
and only ten sub-clones were studied from each sampling.
Supporting Information
Figure S1 Spoligotyping and RFLP pattern of serial clinical
isolates of M. tuberculosis. S99-293=isolate 8, S91-222=isolate 1,
Table 4. Relative fitness expressed as competition indexes
(CI) and frequency of different resistant mutants isolated at
the different time points.
Time (isolate) CI
a Type Frequency
b
1991 (1, parent) 1 (0.7, 1.3) wt 10/10
1991 (3.1) 0.3 (0.3, 0.3) rpsL87AGG 9/10
1991 (3.2) ,0.01 (,0.01,
,0.01)
rrsA513C 1/10
1992 (4.4) 0.3 (0.2, 0.4) rpsL87AGG 10/10
1992 (5) 8 (6, 11) rpsL87AGG 10/10
1993 (6) 0.3 (0.2, 0.4) rpsL42AGG 10/10
1993 (7.1) 0.07 (0.04, 0.1) rpsL42AGG 2/10
1993 (7.2) 1 (1, 1) rrsA513C 8/10
1999 (8) 0.5 (0.3, 0.6) rpsL42AGG,
rrsA1400G
10/10
CIs were determined as described in Materials and Methods.
aNumbers are averages based on two independent measurements (shown
within parantheses).
bFrequency indicates how many of the 10 sub-clones obtained from that
particular time point and isolate carried the specified resistance mutation.
doi:10.1371/journal.pone.0021147.t004
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031=isolate 5, S93-007=isolate 6, S93-021=isolate 7.
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